CME: Interstitial Lung Disease with Progressive Lung Disease Phenotype (ILD-PF): Therapeutic Updates, Best Practices, and Emerging Therapies

CME: Interstitial Lung Disease with Progressive Lung Disease Phenotype (ILD-PF): Therapeutic Updates, Best Practices, and Emerging Therapies is organized by ScientiaCME.

Release Date: January 27, 2019
Expiration Date: January 27, 2021

Accreditation:
Credit Designation
ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.00 hours (0.1 CEUs) of continuing education.

Description:
Interstitial lung disease (ILD) is a collective term used to categorize more than 200 different types of diseases that affect the alveolar structures, the pulmonary interstitium, and small airways. The incidence and prevalence of ILD, as its own entity, are difficult to quantify because of number of different causes and the difficulty diagnosing patients. One form of ILD is associated with an overexpression of adenosine-2B receptor (A2BAR) has been linked to rapid progression of idiopathic pulmonary fibrosis (IPF), a type of IIP, and patients identified with this highly upregulated gene warrants closer monitoring of lung function and disease progression. Known as ILD with progressive lung phenotype (ILD-PF), patients with a number of diseases, such as rheumatoid arthritis and chronic hypersensitivity pneumonitis, are predisposed to this variant. This learning activity has been designed to bring HCPs’ knowledge of the strategies for treatment and management of ILD-PF up to date and to improve their competence and performance in treating it.

Objectives:
By the end of the session the participant will be able to:
• Describe the pathophysiology of and risk factors for ILD-PF such that it might inform treatment mechanisms and strategies
• Identify signs and symptoms of ILD-PF (e.g., rheumatoid arthritis, chronic hypersensitivity pneumonitis, unclassified ILD)
• Describe the prevalence, morbidity, and mortality, burden of illness associated with ILD-PF and, conversely, the benefits associated with early identification and treatment
• Describe current treatment standards and monitoring parameters (HRCT, PFTs) of ILD-PF, including developments in clinical research and treatment guidelines, and apply them to patient cases
• Discuss ways to improve clinician communication with their patients, including disease education